ReviR Therapeutics names new chief scientific officer
4 July 2022 -

ReviR Therapeutics, a US-based biotechnology company, announced on Friday that it has named Paul August, PhD as its new chief scientific officer.

Dr August has over two decades of senior experience in pharmaceutical research and development. He has served as vice president of Discovery Biology at Agios Pharmaceuticals, vice president at Ligand and ICAGEN Pharmaceuticals. He was also the co-founder and chairman of the board of AcuraStem. He has spent much of his career at Sanofi and legacy companies, with roles of increasing responsibility that included lead discovery, as well as target discovery and validation.

Peng Yue, Ph.D., ReviR Therapeutics co-founder and chief executive officer, said, 'We are thrilled to welcome Dr August to our team. Paul has extensive experience in drug discovery through development and regulatory approval. His in-depth knowledge of rare genetic diseases will greatly accelerate our progress towards discovering novel medicines that treat diseases with unmet medical needs.'